

Northern Territory of Australia

*Medicines, Poisons and Therapeutic Goods Act 2012*

**Safety Direct Solutions - SSTP  
Approval**

I, Christopher Paul Burgess, A/Chief Health Officer:

- (a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;
- (b) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated 15/05/2025

Chief Health Officer

## Schedule A

Title	Publication Date	Author
Safety Direct Solutions - SSTP	15 May 2025	Medicines and Poisons, Northern Territory Government, NT Health

# Safety Direct Solutions - SSTP

<b>Areas Applicable</b>	NT Wide	
<b>Health Professionals authorised by this SSTP</b>	Nurses, and Paramedics employed by or contracted to Safety Direct Solutions Pty Ltd (ABN 19 110 817117)	
<b>Scheduled Substance(s)</b>	<div> <div>Adenosine</div> <div>Adrenaline</div> <div>Amiodarone</div> <div>Atropine</div> <div>Ceftriaxone</div> <div>Dexamethasone</div> <div>Droperidol</div> <div>Enoxaparin</div> <div>Furosemide</div> <div>Glucagon</div> <div>Glyceryl Trinitrate</div> <div>Heparin</div> <div>Hydrocortisone</div> <div>Ipratropium</div> <div>Levetiracetam</div> <div>Lidocaine</div> </div> <div> <div>Metaraminol</div> <div>Methoxyflurane</div> <div>Metoclopramide</div> <div>Midazolam</div> <div>Naloxone</div> <div>Noradrenaline</div> <div>Ondansetron</div> <div>Rocuronium</div> <div>Salbutamol</div> <div>Tenecteplase</div> <div>Tranexamic Acid</div> <div><b>Schedule 8 Medicines</b></div> <div>Fentanyl</div> <div>Morphine</div> <div>Ketamine</div> </div>	
<b>Indication, Dose, Route, Frequency</b>	<ul style="list-style-type: none"> <li>Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in the Safety Direct Solutions Pty Ltd Clinical Practice Protocols as in force from time to time.</li> <li>Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner</li> </ul>	
<b>Contraindications and/or Exclusions*</b>	<ul style="list-style-type: none"> <li>Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol</li> <li>Any contraindications or exclusions as outlined in the individual scheduled substance product information</li> <li>Any contraindication or exclusions as outlined in Safety Direct Solutions Pty Ltd Clinical Practice Protocols</li> </ul>	

<b>Health Professional Accreditation Requirements</b>	<u>Nurses must:</u> <ul style="list-style-type: none"><li>• Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients</li><li>• Maintain continuing professional development related to skills and competencies required for delivery of medicines</li></ul> <u>Paramedics must:</u> <ul style="list-style-type: none"><li>• Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients</li><li>• Maintain continuing professional development related to skills and competencies required for delivery of medicines</li></ul>		
<b>Chief Health Officer</b>	<b>Signature</b>	<b>Name</b>	<b>Date</b>
	<b>EDOC2025/117176</b>	Christopher Paul Burgess	15/05/2025
<b>Period of effect</b>	This SSTP is in effect until 15/05/2027 unless revoked earlier		
<b>References:</b> * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			